Previous Close | 1.4100 |
Open | 1.4100 |
Bid | 1.5700 x 900 |
Ask | 1.8200 x 1400 |
Day's Range | 1.3550 - 1.4300 |
52 Week Range | 1.1200 - 13.7700 |
Volume | |
Avg. Volume | 617,266 |
Market Cap | 1.812B |
Beta (5Y Monthly) | 1.29 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.5800 |
Earnings Date | Mar 19, 2024 - Mar 25, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for PROK
WINSTON-SALEM, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Jefferies Biotech on the Bay Summit being held in Miami on March 12 – 13, 2024. The ProKidney management team will host one-on-one meetings during the event. Interested investors should contact their Jefferies
In this article, we discuss Chamath Palihapitiya and the 12 stocks he pumped in the last 10 years. If you want to read about some more Chamath Palihapitiya stocks, go directly to Chamath Palihapitiya Stocks: 5 Stocks Pumped in the Last 10 Years. Chamath Palihapitiya is an investing genius, even though some of his opinions […]
ProKidney Corp. (PROK) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.